Findings

What do systematic reviews say?

2,908 questions · 3,101 findings · 509 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 571 · 18.4%GRADE not reported 358 · 11.5%Very low 723 · 23.3%Low 854 · 27.5%Moderate 489 · 15.8%High 106 · 3.4%

Fludrocortisone vs placebo

Frequency and severity of postural lightheadedness · people with diabetes and orthostatic hypotension

1 finding from 1 review

Fludrocortisone for orthostatic hypotension 2021 · Cochrane Headline outcomes only
no estimate extracted
0 participants
GRADE not reported

Fludrocortisone vs placebo

Frequency of syncope · people with diabetes and orthostatic hypotension

1 finding from 1 review

Fludrocortisone for orthostatic hypotension 2021 · Cochrane Headline outcomes only
no estimate extracted
0 participants
GRADE not reported

Fludrocortisone vs placebo

Quality of life · people with diabetes and orthostatic hypotension

1 finding from 1 review

Fludrocortisone for orthostatic hypotension 2021 · Cochrane Headline outcomes only
no estimate extracted
0 participants
GRADE not reported

Fludrocortisone vs placebo

Serious or severe adverse events · people with diabetes and orthostatic hypotension

1 finding from 1 review

Fludrocortisone for orthostatic hypotension 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 6 participants
Very low

Lower blood pressure targets vs standard blood pressure targets

Total mortality · adult patients with hypertension

Lower BP target showed no clear difference in total mortality compared with standard BP target (high certainty).

1 finding from 1 review

Blood pressure targets in adults with hypertension 2020 · Cochrane Headline outcomes only
RR 0.95 [0.86, 1.05]
Studies not reported
High

Lower blood pressure targets vs standard blood pressure targets

Total serious adverse events№ of participants: 18165(6 RCTs) · adult patients with hypertension

Lower BP target showed no clear difference in total serious adverse events№ of participants: 18165(6 RCTs) compared with standard BP target (moderate certainty).

1 finding from 1 review

Blood pressure targets in adults with hypertension 2020 · Cochrane Headline outcomes only
RR 1.04 [0.99, 1.08]
Studies not reported
Moderate

Lower blood pressure targets vs standard blood pressure targets

Myocardial infarction · adult patients with hypertension

Lower BP target may leads to lower myocardial infarction№ of participants: 38,198(8 RCTs) compared with standard BP target (low certainty).

1 finding from 1 review

Blood pressure targets in adults with hypertension 2020 · Cochrane Headline outcomes only
RR 0.84 [0.73, 0.96]
Studies not reported
Low

Lower blood pressure targets vs standard blood pressure targets

Stroke · adult patients with hypertension

Lower BP target showed no clear difference in stroke№ of participants: 37,087(7 RCTs) compared with standard BP target (low certainty).

1 finding from 1 review

Blood pressure targets in adults with hypertension 2020 · Cochrane Headline outcomes only
RR 0.88 [0.77, 1.01]
Studies not reported
Low

Lower blood pressure targets vs standard blood pressure targets

Congestive heart failure · adult patients with hypertension

Lower BP target may leads to lower congestive heart failure№ of participants: 15,859(5 RCTs) compared with standard BP target (low certainty).

1 finding from 1 review

Blood pressure targets in adults with hypertension 2020 · Cochrane Headline outcomes only
RR 0.75 [0.6, 0.92]
Studies not reported
Low

Lower blood pressure targets vs standard blood pressure targets

Other serious adverse events · adult patients with hypertension

Lower BP target may leads to higher other serious adverse events compared with standard BP target (low certainty).

1 finding from 1 review

Blood pressure targets in adults with hypertension 2020 · Cochrane Headline outcomes only
RR 1.44 [1.32, 1.59]
Studies not reported
Low

Uric acid lowering therapies (UAR) vs placebo

24‐h ambulatory systolic BP · hyperuricaemia in people with hypertension

1 finding from 1 review

Pharmacotherapy for hyperuricaemia in hypertensive patients 2020 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 229 participants
Low

Uric acid lowering therapies (UAR) vs placebo

24‐h ambulatory diastolic BP · hyperuricaemia in people with hypertension

1 finding from 1 review

Pharmacotherapy for hyperuricaemia in hypertensive patients 2020 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 229 participants
Low

Uric acid lowering therapies (UAR) vs placebo

Systolic blood pressure · hyperuricaemia in people with hypertension

1 finding from 1 review

Pharmacotherapy for hyperuricaemia in hypertensive patients 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 120 participants
Low

Uric acid lowering therapies (UAR) vs placebo

Diastolic blood pressure · hyperuricaemia in people with hypertension

1 finding from 1 review

Pharmacotherapy for hyperuricaemia in hypertensive patients 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 120 participants
Low

Uric acid lowering therapies (UAR) vs placebo

Serum UA · hyperuricaemia in people with hypertension

1 finding from 1 review

Pharmacotherapy for hyperuricaemia in hypertensive patients 2020 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 223 participants
High

Uric acid lowering therapies (UAR) vs placebo

Withdrawals due to adverse events · hyperuricaemia in people with hypertension

Uric acid‐lowering drug showed no clear difference in adverse events (withdrawals due to side effects) compared with placebo (low certainty).

1 finding from 1 review

Pharmacotherapy for hyperuricaemia in hypertensive patients 2020 · Cochrane Headline outcomes only
RR 1.86 [0.43, 8.1]
3 studies · 241 participants
Low

Combination therapy vs monotherapy

Total mortality · people with primary hypertension

It is very uncertain whether combination therapy changes total mortality compared with monotherapy (very low certainty).

1 finding from 1 review

First‐line combination therapy versus first‐line monotherapy for primary hypertension 2020 · Cochrane Headline outcomes only
RR 1.35 [0.08, 21.72]
3 studies · 568 participants
Very low

Combination with potassium‐sparing diuretics vs monotherapy

Withdrawals due to adverse events · people with primary hypertension

1 finding from 1 review

First‐line combination therapy versus first‐line monotherapy for primary hypertension 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 200 participants
Very low

Combination therapy vs monotherapy

Cardiovascular mortality · people with primary hypertension

1 finding from 1 review

First‐line combination therapy versus first‐line monotherapy for primary hypertension 2020 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 568 participants
Very low

Combination therapy vs monotherapy

Cardiovascular events · people with primary hypertension

It is very uncertain whether combination therapy changes cardiovascular events compared with monotherapy (very low certainty).

1 finding from 1 review

First‐line combination therapy versus first‐line monotherapy for primary hypertension 2020 · Cochrane Headline outcomes only
RR 0.98 [0.22, 4.41]
3 studies · 568 participants
Very low